Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

NCT05242822 is registered in ClinicalTrials.gov with Kinnate Biopharma as lead sponsor.

NCT NCT05242822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05242822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Lead sponsor
Kinnate Biopharma
Phase
Phase 1
Overall status
Terminated
Start date
March 29, 2022
Completion date
October 3, 2024
Enrollment
54 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma, solid tumor, adult, urothelial carcinoma